Get E&O weekly. | Subscribe
Digital health research from Brian Dolan.
Welcome to E&O.
Last week's newsletter had a 62 percent open rate. Here's what's happening this week:
- Once again you're looking at a COVID--19-free newsletter. That will be the only mention of it here. There's plenty of other things to read and think about so let's get right onto it...
- Regrets, I've had a few: Last week I dashed off a headline for the Livongo year-in-review piece and flubbed the company's year-over-year multiple. Livongo's revenues grew 2.5x between 2018 and 2019, not 1.5x as I wrote in the headline. All of the other information in the article was correct. Apologies for the mistake and thanks to the reader who pointed it out. Eager to hear when I'm wrong, so please don't hesitate to tell me.
- Speaking of righted wrongs, BCG's white paper on digital therapeutics that I mentioned last week